CareFusion

CareFusion
Share
CareFusion combines technology and intelligence to measurably improve patient care. Our clinically proven products are designed to help improve the safety and cost of healthcare for generations to come. Some of our most trusted brands include Alaris®, ChloraPrep®, Pyxis®, V. Mueller®, and VIASYS.

CareFusion

 •  June 6

Extends BD MAX™ Enteric Panel Portfolio with latest Molecular Test that Targets Infectious Diarrhea
FRANKLIN LAKES, N.J., June 5, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its newly developed molecular test for detecting harmful intestinal bacteria causing infectious...

CareFusion

 •  April 27

Mass spectrometry identification solution may help hospitals manage antimicrobial resistance more effectively
FRANKLIN LAKES, N.J., Apr. 27, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global distribution of a complete portfolio of products for mass spectrometry that...

CareFusion

 •  April 24

FRANKLIN LAKES, NJ and MURRAY HILL, NJ (April 23, 2017) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a definitive agreement under which BD...

CareFusion

 •  April 4

Expands Infusion Portfolio for Ambulatory, Home Care and Specialty Applications
FRANKLIN LAKES, N.J., April 4, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems...

CareFusion

 •  April 3

BD Showcases Solutions and Technologies to Improve Patient Safety Across the Continuum of Care at #EAHP2017
CANNES, March 22, 2017 — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medication technology company, announced today the availability of its new IV Medication Safety Solution, designed to help to measurably prevent IV...

CareFusion

 •  April 3

Visit booth #1115 to learn about the BD program focused on improving education, process and efficiency to impact patient safety
BOSTON, M.A., April 3, 2017 — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its quality improvement program, BD “Power in Prevention” at the Association of...

CareFusion

 •  February 22

Health care providers and laboratories may be better equipped to test and treat patients during the flu season
FRANKLIN LAKES, N.J., Feb. 22, 2017 – Effective Feb. 13, 2017, the Food and Drug Administration (FDA) has reclassified antigen based rapid influenza virus antigen detection systems (RIDTs) intended to detect influenza virus directly from...

CareFusion

 •  January 24

Indication for Congestive Heart Failure on Display at the 2017 Society of Thoracic Surgeons (STS) Meeting
FRANKLIN LAKES, N.J., JAN. 23, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its PleurX™ catheter system received U.S. Food and Drug Administration (FDA) 510(k) clearance...

CareFusion

 •  December 15, 2016

New BD Neopak™ 2.25 mL Prefillable Glass Syringe Helps Improve Safety and Convenience for Patients
FRANKLIN LAKES, N.J., DEC. 15, 2016 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Neopak™ 2.25 mL prefillable glass syringe, specifically designed for...

CareFusion

 •  November 18, 2016

Franklin Lakes, NJ (November 14, 2016) – BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will host an institutional investor and analyst meeting on Thursday, November 17, 2016 in New York City from 8:30 a.m. – 3:30 p.m. (ET). The meeting will update the investment community on BD’s plans to create long term value for its...